Ensign Peak Advisors
ABCL icon

Ensign Peak Advisors’s AbCellera Biologics ABCL Stock Holding History

Ensign Peak Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-166,000
Closed -$764K – 1739
2023
Q3 		$764K Hold
166,000
– – ﹤0.01% 1397
2023
Q2 		$1.07M Hold
166,000
– – ﹤0.01% 1198
2023
Q1 		$1.25M Hold
166,000
– – ﹤0.01% 1071
2022
Q4 		$1.68M Buy
+166,000
New +$1.92M ﹤0.01% 879

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Ensign Peak Advisors's ABCL Position: Q4 2023 in Review

Ensign Peak Advisors sold out of AbCellera Biologics (ABCL) in Q4 2023, closing a stake of 166,000 shares — an estimated $764K sold.

Ensign Peak Advisors first reported a position in ABCL in Q4 2022 and held it in 4 quarters. The position peaked at $1.68M in Q4 2022. 142 funds tracked by Wall St. Rank hold ABCL as of Q4 2023.

  • Ensign Peak Advisors reported no remaining AbCellera Biologics position as of Q4 2023 after selling out during the quarter.
  • Ensign Peak Advisors sold 166,000 AbCellera Biologics shares in Q4 2023, an estimated $764K.
  • Ensign Peak Advisors first reported a position in AbCellera Biologics in Q4 2022 and held it in 4 quarters.
  • Ensign Peak Advisors's AbCellera Biologics position peaked at $1.68M in Q4 2022.
  • 142 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2023.

Based on Ensign Peak Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.